Reata Pharmaceuticals amends bylaws to update director nomination procedures and exclusive forum provisions

REATA PHARMACEUTICALS INC

Board of Directors approved Third Amended and Restated Bylaws effective March 1, 2023.
Amendments revise procedures and disclosure requirements for director nominations to comply with SEC Rule 14a-19.
Bylaws designate federal district courts as exclusive forum for Securities Act of 1933 claims.
Updates made to indemnification provisions and other administrative changes to conform with Delaware General Corporation Law.
Exhibit 3.1 filed with the 8-K contains the full text of the Amended and Restated Bylaws.

item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

REATA PHARMACEUTICALS INC: 董事会批准了第三次修订和重述的公司章程，包括修改董事提名程序、通知程序、专属法庭条款、赔偿条款及其他行政性变更。 (effective 2023-03-01).

Change: bylaw amendment
Effective: 2023-03-01

Exact text from the filing

On March 1, 2023, the Board of Directors of Reata Pharmaceuticals, Inc. (the “Company”) approved the Company’s Third Amended and Restated Bylaws (“Amended and Restated Bylaws”), effective as of such date.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0000950170-23-005600

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.